EMA provides guidelines for another unauthorized Covid-19 tablet

On Thursday, the European Medicines Agency (EMA) issued advice pertaining to Pfizer's Covid-19 tablet treatment Paxlovid, prior to market approval. The same day, Denmark allowed the use of MSD's similar treatment, Lagevrio.

Photo: HANDOUT/AFP / Pfizer

On Thursday, as Denmark decided to allow use of MSD's Lagevrio (molnupiravir) a pill treatment that has not yet been approved by the European Medicines Agency (EMA), the agency decided to issue advice for another unauthorized drug.

The EMA has now provided guidelines for Pfizer's tablet treatment Paxlovid in a press release that entails the situations in which the drug can be used. Member states that choose to use the treatment prior to its market approval may do so supported by the EMA's advice.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs